Etoposide Capsules POSID

[Drug Name] Etoposide Capsules

[English Name] Etoposide Capsules

[Specification] 50 mg × 8 capsules/box

[Active Ingredient] Etoposide

Etoposide Capsules are an antineoplastic medication primarily used clinically to treat conditions such as small cell lung cancer and malignant lymphoma. Typically, the medication should be taken under a physician's guidance for 3 to 6 treatment cycles, depending on the patient's specific medical condition. This product is packaged with 8 capsules per box; approximately 3 boxes constitute one full treatment cycle (typically lasting 21 days). It is recommended to purchase enough medication for at least two treatment cycles to ensure continuity of care and avoid interruptions in follow-up treatment. For most patients, Etoposide Capsules begin to take effect approximately 20 minutes after administration, and significant symptom relief is typically observed by the third day of treatment. However, to achieve optimal therapeutic results, the medication is usually administered in combination with intravenous 5-fluorouracil agents (e.g., Capecitabine, which is available for purchase in this store).

1. Early-Stage Small Cell Lung Cancer: For patients with early-stage small cell lung cancer—particularly those with mild disease—Etoposide Capsules may be used as a standalone treatment. Typically, positive results are observed by the third day of administration, leading to the alleviation of symptoms such as coughing, expectoration, and hemoptysis, while also contributing to a corresponding extension of the patient's survival period.

2. Locally Advanced or Metastatic Small Cell Lung Cancer: For patients with locally advanced or metastatic small cell lung cancer, following an initial course of 2 to 3 cycles of combination therapy, treatment involving Etoposide Capsules combined with Azithromycin or Paclitaxel can yield favorable results for the majority of patients, with a median survival period reaching approximately 2 years.

3. Refractory or Recurrent Small Cell Lung Cancer: For patients in this category—specifically those who show a poor response after completing 2 to 3 cycles of combination therapy—second-line treatment options may be selected. These options include medications such as Irinotecan or Tegafur-Gimeracil-Oteracil Potassium Capsules. While such treatments can extend the patient's survival period, complete remission or a definitive cure is typically difficult to achieve.

4. Other Circumstances: If a patient experiences adverse reactions or allergic responses to Etoposide Capsules—such as nausea or vomiting—continued use of this medication for treatment is not recommended. In such cases, alternative therapeutic agents—such as Crizotinib—may be selected instead. Furthermore, patients taking Etoposide capsules are advised to closely monitor their physical condition and take the medication strictly under a physician's guidance. They should avoid self-medication or taking the drug blindly to prevent the occurrence of adverse reactions. Additionally, during the course of treatment, patients should prioritize rest and avoid staying up late or engaging in strenuous activities. Moderate physical exercise is also encouraged, as it helps improve overall physical fitness and facilitates recovery from the disease.

【Indications】 Small cell lung cancer, malignant lymphoma, acute leukemia, testicular tumors, bladder cancer, choriocarcinoma, etc.

【Dosage and Administration】

1. As a single agent: 60–100 mg/m² daily for 10 consecutive days, repeated every 3–4 weeks. In combination chemotherapy: 50 mg/m² per day for 3 or 5 consecutive days. This medication is highly toxic; it must be taken strictly under the guidance of a physician. Please strictly adhere to medical instructions to ensure therapeutic efficacy and minimize the risk of side effects.

2. Etoposide capsules are supplied in 50 mg units. The standard regimen for adults is typically 100 mg (2 capsules) daily for 5 consecutive days, followed by a 3-week drug-free interval; *alternatively*, 50 mg (1 capsule) daily for 21 consecutive days, followed by a 1-week drug-free interval. Each of these constitutes one treatment cycle. The medication may be administered repeatedly, with the dosage adjusted appropriately based on the patient's clinical condition and the specific type of disease. This medication is highly toxic; it must be taken strictly under the guidance of a physician. Please strictly adhere to medical instructions to ensure therapeutic efficacy and minimize the risk of side effects.

3. Generally, the adult dosage is 50–100 mg of Etoposide capsules taken orally daily for 14 or 21 consecutive days; *alternatively*, 50 mg/m² taken orally daily for 14 or 21 consecutive days. This is followed by a 1–2 week drug-free interval, constituting one treatment cycle. The medication may be administered repeatedly, with dosages adjusted appropriately based on the patient's clinical condition and the specific type of disease; typically, 2–3 treatment cycles are administered. This medication is highly toxic; it must be taken strictly under the guidance of a physician. Please strictly adhere to medical instructions to ensure therapeutic efficacy and minimize the risk of side effects.

【Adverse Reactions】 1. Hematologic: Leukopenia (decreased white blood cell count), thrombocytopenia (decreased platelet count), hemorrhage, and anemia. 2. Hepatic: Occasional abnormalities in liver function tests, such as elevated levels of GOT (AST), GPT (ALT), alkaline phosphatase (ALP), and bilirubin. 3. Renal System: Occasionally, elevated BUN and creatinine levels may occur. 4. Digestive System: Occasionally, symptoms such as nausea, vomiting, loss of appetite, stomatitis, abdominal pain, diarrhea, and constipation may occur. 5. Hypersensitivity Reactions: Occasionally, symptoms such as skin rashes may occur. 6. Skin: Occasionally, severe hair loss, erythema, and pruritus may occur. 7. Nervous System: Occasionally, symptoms such as numbness in the extremities and headaches may occur. 8. Circulatory System: ECG changes, arrhythmias, and symptoms of hypotension may occur. 9. Respiratory System: Interstitial pneumonia may occur. 10. Other: Occasionally, symptoms such as fatigue and fever may occur.

[Contraindications] 1. Patients with severe bone marrow suppression. 2. Patients with a history of severe hypersensitivity reactions to this preparation.

[Precautions] 1. General Precautions: 1. Since severe adverse reactions—such as bone marrow suppression—may occasionally occur, frequent clinical monitoring (including blood counts and renal function tests) should be performed. The patient's condition should be closely observed; if abnormalities are detected, measures such as dose reduction or discontinuation of the drug should be implemented. Furthermore, because long-term use carries a high risk of adverse reactions—which may sometimes result in persistent or delayed effects—the drug should be administered with extreme caution. 2. Close attention should be paid to the onset or exacerbation of infections and bleeding tendencies. 3. When administering to pediatric patients, particular attention should be paid to the emergence of adverse reactions, and the drug should be administered with caution. 4. If continuous administration is deemed necessary for pediatric patients or patients of reproductive age, potential effects on gonadal function should be carefully considered. 2. The drug should NOT be administered to the following patients: 1. Patients with severe bone marrow suppression. 2. Patients with a history of severe hypersensitivity reactions to this drug. The drug should be administered with caution to the following patients: 1. Patients with existing bone marrow suppression. 2. Patients with impaired hepatic function. 3. Patients with impaired renal function. 4. Patients with concurrent infections. 5. Patients with varicella (chickenpox) (as this may occasionally lead to fatal systemic complications).

[Drug Interactions] When used in combination with other antineoplastic agents or radiation therapy, adverse reactions—such as bone marrow suppression—may occasionally be exacerbated. [Pharmacological Action] This product is a cell-cycle-specific antineoplastic agent that acts on DNA topoisomerase II, forming a stable, reversible drug-enzyme-DNA complex that inhibits DNA repair. Experimental studies have shown that this complex can be reversed upon clearance of the drug, allowing damaged DNA to be repaired and thereby reducing cytotoxic effects. Consequently, extending the duration of drug administration may enhance its antineoplastic activity.

[Storage] Store at room temperature; high temperatures should be strictly avoided.

Product Specifications

Product Name: Etoposide Capsules (POSID / VP-16) — 50 mg, 8 Capsules/Box

Common Name: Etoposide Soft Capsules

Composition: Etoposide

Dosage Form: Capsules

Specification: 50 mg × 8 capsules/box

Manufacturer: CADILA PHARMACEUTICALS LTD

Indications: Primarily used for the treatment of small cell lung cancer, malignant lymphoma, malignant germ cell tumors, and leukemia. It also demonstrates therapeutic efficacy against neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer, and esophageal cancer.

Usage and Dosage: 1. Etoposide Capsules are supplied in a strength of 50 mg per capsule. The standard regimen for adults involves taking 200 mg (4 capsules) daily for 5 consecutive days, followed by a 3-week drug-free interval; alternatively, 50 mg (1 capsule) may be taken daily for 21 consecutive days, followed by a 1-week drug-free interval. Each of these constitutes one treatment cycle. Treatment may be repeated, with the dosage adjusted appropriately based on the patient's condition and the specific type of disease. Please strictly adhere to your physician's instructions to ensure optimal efficacy and minimize the risk of adverse effects.

2. Generally, the adult dosage is 50–100 mg of Etoposide taken orally daily for 14 or 21 consecutive days; alternatively, 50 mg/m² of body surface area may be taken orally daily for 14 or 21 consecutive days. This is followed by a 1–2 week drug-free interval to complete one treatment cycle. Treatment may be repeated, with dosages adjusted as appropriate based on the patient's condition and the specific type of disease; typically, a course of 2 to 3 cycles is administered.